Prodrug design for the potent cardiovascular agent Nω-hydroxy-l-arginine (NOHA): Synthetic approaches and physicochemical characterization

Reduction ofNω-hydroxy-L-arginine by the mitochondrial amidoxime reducing component (mARC)

(2010) Jürke Kotthaus et al.   BIOCHEMICAL JOURNAL

Modulating the NO generating system from a medicinal chemistry perspective: Current trends and therapeutic options in cardiovascular disease

(2010) Dennis Schade et al.   PHARMACOLOGY & THERAPEUTICS

New Treatment Option for Second-Stage African Sleeping Sickness: In Vitro and In Vivo Efficacy of Aza Analogs of DB289

(2009) T. Wenzler et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

The Peptidylglycine α-Amidating Monooxygenase (PAM): A Novel Prodrug Strategy for Amidoximes andN-Hydroxyguanidines?

(2009) Dennis Schade et al.   ChemMedChem

Endothelial Function and Oxidative Stress in Cardiovascular Diseases

(2009) Yukihito Higashi et al.   CIRCULATION JOURNAL

Structure–activity relationship of novel and known inhibitors of human dimethylarginine dimethylaminohydrolase-1: Alkenyl-amidines as new leads

(2008) Jürke Kotthaus et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Vascular System: Role of Nitric Oxide in Cardiovascular Diseases

(2008) Ka Bian et al.   Journal of Clinical Hypertension

NG-Aminoguanidines from Primary Amines and the Preparation of Nitric Oxide Synthase Inhibitors

(2008) Nathaniel I. Martin et al.   JOURNAL OF MEDICINAL CHEMISTRY

Nδ-Methylated l-arginine derivatives and their effects on the nitric oxide generating system

(2007) Jürke Kotthaus et al.   BIOORGANIC & MEDICINAL CHEMISTRY